Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood - United States
doi 10.1182/blood-2019-01-896290
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy
OncologyPharmacology
2015English

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy